Daniel L. Clarke‐Pearson
University of North Carolina at Chapel Hill · 274 works · 47,352 citations · h-index 67
Top works
- Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
- Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
- Randomized Comparison of Fluorouracil Plus Cisplatin Versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix With Negative Para-Aortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
- Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
- American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
- Overexpression and mutation of p53 in epithelial ovarian cancer.
- Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer
- Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma
- Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study
- Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease
- Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.
- Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group
- Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology
- Spectrum of Mutation and Frequency of Allelic Deletion of the p53 Gene in Ovarian Cancer
- Elevation of Multiple Serum Markers in Patients With Stage I Ovarian Cancer
- Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma
- Screening for Ovarian Cancer